Restoring Brain Energy Reverses Alzheimer’s Pathology in Mice and Points to Clinical Recovery Pathways

For more than a century Alzheimer’s disease (AD) has been treated as an irreversible neurodegenerative disorder. A multi-institutional team led by investigators at University Hospitals and Case Western Reserve University recently reported that restoring cerebral nicotinamide adenine dinucleotide (NAD⁺) homeostasis with a small-molecule pharmacologic agent reversed advanced AD pathology and restored cognitive function in two distinct mouse models. 

Published in Cell Reports Medicine on January 20, the paper presents convergent evidence from mouse models, human brain proteomics, and biomarker readouts that implicate failure of NAD⁺-based energy homeostasis as a major, potentially reversible driver of late-stage disease. The authors also propose tractable translational paths for testing AD in clinical settings. 

Background, Study Design and Translational Strategy

Alzheimer’s research has historically prioritized prevention and slowing of decline because dementia in advanced stages has been viewed as permanent. The new study reframes that dogma by asking whether brains already exhibiting advanced amyloid- and tau-driven pathology can be physiologically repaired and functionally recovered if core cellular energy deficits are corrected. The investigators ground their hypothesis in earlier work showing NAD⁺ preservation supports neuronal survival and recovery after severe traumatic brain injury.

The team responsible for the current study is led by Prof. Andrew Pieper from the Department of Psychiatry, Case Western Reserve School of Medicine. They used two genetically distinct mouse models that respectively model amyloid and tau pathology, permitting a test of whether an intervention targeting cell-energetic mechanisms can act across canonical AD pathologies. They combined behavioral assays (memory and learning), neuropathology measures (amyloid, phosphorylated tau, synaptic integrity), blood biomarkers, vascular assessments, and targeted proteomic analyses of human AD brain datasets to triangulate mechanism and translational potential. 

Importantly, the study tested both prophylactic NAD⁺ preservation and delayed treatment after animals had established, advanced disease, which was a design intended to mirror clinical reality for symptomatic AD patients.

How NAD⁺ Balance Drives Brain Health and Alzheimer’s Recovery

NAD⁺ is a molecule that cells rely on to produce energy and to support essential functions such as repairing DNA, defending against oxidative damage, and maintaining normal cell signaling. The researchers found that NAD⁺ levels naturally decline with age, and that this decline is much more pronounced in the brains of people with AD and in the mouse models used in the study. Rather than simply increasing NAD⁺ levels in a nonspecific way, the team used a targeted drug called P7C3-A20. 

This brain-penetrant small-molecule compound was developed by the research group led by Prof. Pieper, which specializes in discovering small-molecule drugs designed to protect neurons and preserve brain function under stress. It works by helping brain cells maintain their normal NAD⁺ balance when they are under disease-related stress, without forcing NAD⁺ to rise above normal physiological levels. By stabilizing NAD⁺ in this way, the treatment restored cellular energy production and activated protective pathways that support neuron survival and function.

Pathology Reversed, Function Restored in Mouse Models

The most important finding was that giving P7C3-A20 to mice that already had advanced, symptomatic AD led to broad improvements in brain health. The targeted treatment reduced signs of brain inflammation, helped restore the integrity of the blood–brain barrier, improved communication between neurons, supported the generation of new neurons in the hippocampus, and lowered oxidative stress. 

These biological improvements were accompanied by a full recovery of memory and learning performance in behavioral tests. The researchers also observed that levels of phosphorylated tau-217 (p-tau217) in the blood returned toward normal as the animals recovered, indicating that this blood marker could be used to track treatment response in future studies. Importantly, the same pattern of recovery was seen in both amyloid-based and tau-based AD mouse models.

Evidence from Human Brain Data and Implications for AD Treatment

To better understand how their findings might translate to patients, the researchers analyzed large, previously published datasets from human AD brains. They focused on protein changes and found recurring patterns affecting mitochondria (the cell’s energy producers), synapses (the connections between neurons), and blood vessels in the brain. All of these systems were linked to disrupted NAD⁺ balance, suggesting that problems with cellular energy metabolism are also present in human AD.

The team also examined gene activity in brains from people who had clear Alzheimer’s pathology at autopsy but had remained cognitively normal during life. In these individuals, gene-expression patterns indicated that NAD⁺ levels and related energy pathways were better preserved. This finding suggests that maintaining NAD⁺ balance may help protect the brain from cognitive decline. Together, these human data support the idea that restoring NAD⁺ homeostasis could potentially modify the course of AD in patients, not just in animal models.

Limitations and Scientific Caution

Despite the strong results seen in animal studies, significant challenges remain before this approach can be applied to patients. Mouse models capture some key aspects of Alzheimer’s disease, but they do not fully reflect the complexity of the human condition, including aging, coexisting diseases, and the slow progression of Alzheimer’s over many years. 

In addition, drugs in the P7C3 family still need careful testing to understand their safety, how they are processed in the body, and how long they remain active, first in larger animals and then in humans. Although earlier studies suggest these compounds are generally safe in preclinical settings, they have not yet been proven safe or well tolerated in people. Researchers also emphasize that successfully reversing brain pathology in mice does not necessarily mean the same long-lasting benefits will occur in patients, and potential unintended effects on metabolism must be thoroughly evaluated.

Path to the Clinic and Next Steps

Overall, the study highlights two practical advantages for moving this approach toward human testing. First, the blood biomarker p-tau217 changed in parallel with brain recovery in animals, suggesting it could be used as a clear and measurable indicator of treatment response in early clinical trials. Second, by targeting NAD⁺ balance, this strategy addresses a fundamental energy problem in brain cells rather than focusing on a single disease protein, which means it could potentially be used alongside existing Alzheimer’s therapies. 

“This new therapeutic approach to recovery needs to be moved into carefully designed human clinical trials to determine whether the efficacy seen in animal models translates to human patients,” said Prof. Pieper. “Additional next steps for the lab research include pinpointing which aspects of brain energy balance are most important for recovery, identifying and evaluating complementary approaches to Alzheimer’s reversal, and investigating whether this recovery approach is also effective in other forms of chronic, age-related neurodegenerative disease.”

Author

Richard Chau